03-09-2009 Neublastin enters Phase I clinical development as a novel treatment for neuropathic pain


NsGene A/S today announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field of peripheral nervous system disorders, has entered into Phase I clinical development for the treatment of neuropathic pain. The first patient in the Phase I trial has been dosed at the University of Adelaide in Australia. A total of 28 patients are expected to be enrolled in the study, which will be conducted and sponsored by Biogen Idec to evaluate the safety and tolerability of Neublastin. The initiation of the Phase I trial triggers a milestone payment to NsGene from Biogen Idec.

 

Teit E. Johansen, CEO of NsGene, said, “The initiation of this Phase I trial is a significant milestone for NsGene, since Neublastin is the first program from our unique pipeline of proprietary neurotrophic factors to make the important transition into clinical development.”

 

“We are thrilled with the successful collaboration with Biogen Idec. Neublastin now stands as one of the most promising and exciting product opportunities for the treatment of neuropathy and associated pain, targeting millions of patients with unmet medical needs,” added Lars U. Wahlberg, COO of NsGene.

 

“Biogen Idec is dedicated to developing pioneering treatments for patients with neurological diseases, and Neublastin represents a potentially first-in-class therapy for restoration of damaged nerves that cause pain. We are excited that the Phase I trial of Neublastin has commenced,” said Gilmore O’Neill, Senior Director, Experimental Neurology, Biogen Idec.

 

Neublastin is a novel and potentially disease-modifying therapeutic protein for the treatment of neuropathic pain that afflicts millions of people worldwide. Neuropathic pain is a major debilitating consequence of nerve damage and the existing treatments are largely ineffective. Neuropathic pain is commonly caused by diabetes and herpes zoster infection. Other causes are amputation, failed back syndromes, cancer-induced nerve compression and chemotherapy.

 

 

For further information please contact:          

Teit E. Johansen, President & CEO

Telephone: +45 44 60 89 48; Fax: +45 44 60 89 89

E-mail: tej@nsgene.dk 

 

 

Background

NsGene A/S (www.nsgene.dk) is a privately held Danish biotechnology company founded in December 1999 as a spin-off from NeuroSearch A/S [OMX Nordic: NEUR]. NsGene develops new therapies for neurological diseases with high needs for efficacious treatments, including Alzheimer’s disease, Parkinson’s disease, and intractable epilepsy. Established and novel proteins, including antibodies, can be delivered to the brain with NsGene’s competitive and proprietary EC Biodelivery™ platform.

 

The major shareholders of NsGene include NeuroSearch A/S, Sunstone Capital A/S, Omega Funds, and LD Pensions. 

 

 


NsGene A/S · Baltorpvej 154 · 2750 Ballerup · Denmark · info@nsgene.dk
NsGene Inc. · 225 Chapman St. · Providence, RI 02905-4533 · USA · info@nsgene.us